The bnp and ntprobnp market has seen considerable growth due to a variety of factors.
•In recent times, there has been a significant expansion in the market size of bnp and ntprobnp. This market, which was worth $2.01 billion in 2024, is projected to increase to $2.26 billion in 2025, representing a compound annual growth rate (CAGR) of 12.6%.
Factors contributing to the growth during the historical period include the increase in the ageing population, the application of these tests in diagnosing heart failure, advancements in cardiovascular medicine, and an emphasis on preventive healthcare.
The bnp and ntprobnp market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for bnp and ntprobnp is projected to experience speedy expansion in the ensuing years, shooting up to "$3.6 billion in 2029, with a compound annual growth rate (CAGR) of 12.3%.
The growth anticipated in the forecast period can be ascribed to factors like the rise in cardiovascular disease incidence, incorporation into point-of-care testing, widened usages in different medical contexts, strategies focusing on personalized medicine, telemedicine, and remote monitoring. Significant trends during the forecast period encompass advancements in assay technology, strategies focusing on personalized medicine, prognostic prediction using biomarkers, the appearance of new biomarkers, and efforts towards international standardization.
The surge in cardiovascular diseases is anticipated to fuel the expansion of the BNP and NTproBNP market in the future. Cardiovascular diseases refer to conditions that impact the heart and blood vessels including peripheral arterial disease, cerebrovascular disease, coronary heart disease, and others. BNP and NTproBNP tests focus on monitoring the heart's health and safety, identify factors leading to cardiovascular disease prior to its manifestation, thereby aiding in implementing preventative actions and decreasing mortality risks. For example, the Centers for Disease Control and Prevention (CDC), a US-based government organization, reported in May 2024 that a death related to cardiovascular disease takes place every 33 seconds, with heart disease accounting for 702,880 deaths in 2022, roughly corresponding to one in five deaths. The escalating occurrence of cardiovascular diseases is steering the BNP and NTproBNP markets.
The bnp and ntprobnp market covered in this report is segmented –
1) By Type: BNP (Brain Natriuretic Peptide), NT-proBNP (N-terminal Pro–B-Type Natriuretic Peptide)
2) By Location Of Testing: Point Of Care Testing, Laboratory Testing
3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Other Applications
Subsegments:
1) By BNP (Brain Natriuretic Peptide): BNP Testing Kits, Point-Of-Care BNP Testing Devices, Laboratory BNP Assays
2) By NT-ProBNP (N-Terminal Pro–B-Type Natriuretic Peptide): NT-ProBNP Testing Kits, Point-Of-Care NT-proBNP Testing Devices, Laboratory NT-ProBNP Assays
The development of innovative products is a growing trend within the BNP and NTproBNP fields. In order to maintain their relevancy and competitiveness, big name companies within these markets are launching new and inventive products. For instance, in May 2023, a health, toxicology, and diagnostics company based in the UK called Randox Laboratories, offered a new diagnostic test for heart failure known as BNP1-32. This automated test allows for the measuring of BNP (B-type natriuretic peptide) levels, a protein produced by the heart and blood vessels, with a high degree of sensitivity and specificity. This test is accompanied by the Acusera range of third-party controls and the Acusera 24.7 software, which are used for the tracking and representation of QC data. The BNP test offers an independent and unbiased evaluation of analytical performance, thus ensuring BNP testing is both reliable and accurate.
Major companies operating in the bnp and ntprobnp market include:
• Abbott Laboratories
• Gentian Diagnostics ASA
• Siemens AG
• PerkinElmer Inc.
• Biomerieux SA
• Quidel Corporation
• Bio-Rad Laboratories Inc.
• F Hoffman La Roche Ltd.
• CTK Biotech Inc.
• RayBiotech Life Inc.
• BHR Pharmaceuticals Ltd.
• Getein Biotech Inc.
• VACURE Biotechnology Co. Ltd.
• Bio-Techne Co.
• Xiamen Biotime Biotechnology Co. Ltd.
• Scripps Laboratories Inc.
• Danaher Corporation
• Beckman Coulter Inc.
• Thermo Fisher Scientific Inc.
• Randox Laboratories Ltd.
• LSI Medience Corporation
• Shionogi & Co. Ltd.
• Radiometer Medical ApS
• Ortho Clinical Diagnostics
• Tosoh Corporation
• Aidian Oy
• Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
• Becton Dickinson and Company
• Acon Laboratories Inc.
• Response Biomedical Corp.
• Nanomix Inc.
• Cepheid Inc.
• Alere Inc.
Asia-Pacific was the largest region in the BNP and NTproBNP market in 2024.North America is expected to be the fastest-growing region in the global BNP and NTproBNP market report during the forecast period. The regions covered in the BNP and NTproBNP market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa